David C Dvorak Invests $5 Million in THINK Surgical

David C Dvorak investment was completed through Black Lake Expeditions, LLC, an entity for which Mr. Dvorak serves as managing director. Mr. Dvorak became THINK Surgical’s Executive Chairman of the Board last year following an extensive search process.

David C Dvorak had a successful 16-year career at Zimmer Biomet Holdings, Inc. where he most recently held the position of president and chief executive officer for a decade.

“Since becoming THINK Surgical’s Chairman, I have gained a much deeper understanding of THINK’s overarching strategy and vision, current product offering and future technology pipeline, as well as the strength of its leadership team,” said Mr. Dvorak.  “Given his track record of success over decades with Stryker Corporation, including his time as president of the Joint Replacement Division and his experience with Mako robotic-arm technology, Stuart Simpson is uniquely qualified to lead THINK. I am highly confident that under Stuart’s leadership THINK will execute its compelling plans with precision and generate tremendous value for its stakeholders.”

“It is incredibly gratifying and motivating to receive such a significant demonstration of support from David,” said Stuart Simpson, president and chief executive officer of THINK Surgical.  “David’s decades of leadership experience in the orthopedic industry makes his investment a testament to the future growth potential of THINK Surgical.”

About THINK Surgical, Inc.
THINK Surgical, Inc., a privately held U.S.-based medical device and technology company, develops, manufactures, and markets active robotics for orthopedic surgery. The TSolution One® Total Knee Application includes the only commercially available, active robot for total knee arthroplasty (TKA) utilizing an open implant library, supporting a variety of implant options.  The core technology of the TSolution One has been used in thousands of successful total joint replacements worldwide.

THINK Surgical actively collaborates with healthcare professionals around the globe to refine our orthopedic products, improving the lives of those suffering from advanced joint disease with precise, accurate, and intelligent technology.  Please refer to the instructions for use for the TSolution One Total Knee Application for a complete list of indications, contraindications, warnings, and precautions.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

MMI notes the funds will support commercialization of the Symani® Surgical System in high-growth markets and continued investment in studies that generate clinical evidence and enable indication expansion. Investments will also accelerate advanced technology capabilities and enable MMI to scale its operational capabilities globally.
“We are excited to begin our journey as a public company with this additional investment. We believe Tevogen’s patient-centric approach, which merges a focus on affordability with advanced science, is a blueprint for sustainable success in the current era of healthcare. I am pleased that investors now have the opportunity to participate in Tevogen’s mission to become the very first life science company offering commercially attractive and affordable personalized T cell therapies for large patient populations in virology, oncology, and neurology, said the CEO of Tevogen Bio.
MB2 Dental notes the financing will be used to fund upcoming acquisitions and future growth for the company, following a record year of growth in 2023 with 150 new partnerships.
Procyrion notes the funding will support the DRAIN-HF pivotal IDE trial evaluating the company's Aortix pump, internal R&D programs to improve manufacturability, and commercialization preparation.
PhotoniCare, in January of this year, announced that the U.S. Food and Drug Administration had granted clearance for its TOMi™ Scope for non-invasive imaging of the middle ear.

By using this website you agree to accept Medical Device News Magazine Privacy Policy